LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome

Haematologica

Volumn 96, Issue 7, 2011, Pages 980-986

  Malumbres, Raquel ^a   Fresquet, Vicente ^a   Roman Gomez, Jose ^b   Bobadilla, Miriam ^a   Robles, Eloy F ^a   Altobelli, Giovanna G ^a,c   Calasanz, M José ^d   Smeland, Erlend B ^e   Aznar, Maria Angela ^a   Agirre, Xabier ^a   Martin Palanco, Vanesa ^b   Prosper, Felipe ^a,f   Lossos, Izidore S ^g   Martinez Climents, Jose A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF NAVARRA   (Spain)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

Acute leukemia; B lymphocytes; Gene expression; Prognostic factor

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BCR ABL GENE; CHILD; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; HEMATOPOIETIC CELL; HUMAN; IMMUNOPHENOTYPING; INFANT; KARYOTYPE; LMO2 GENE; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MLL GENE; ONCOGENE; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TEL AML1 GENE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; B-LYMPHOCYTE SUBSETS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; INFANT; KARYOTYPING; METALLOPROTEINS; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960028424     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.040568     Document Type: Article

References (25)

1. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA. 1998;95(7):3890-5.
2. Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, et al. The oncoprotein LMO2 is expressed in normal germinalcenter B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636-42.
3. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA. 1991;88 (10):4367-71.
4. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10):3520-9.
5. Grutz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 1998;17(16):4594-605.
6. Fisch P, Boehm T, Lavenir I, Larson T, Arno J, Forster A, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 1992;7(12):2389-97.
7. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350 (9):913-22.
8. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26(3):447-54.
9. Sonmez M, Akagun T, Cobanoglu U, Topbas M, Erkut N, Yilmaz M, et al. Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. Hematology. 2009; 14(4):220-3.
10. Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, et al. LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia. 2009; 11(7):712-9.
11. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371 (9617):1030-43.
12. Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Perez-Hurtado JM, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol. 2007;25(1):16-24.
13. Ribera JM, Ortega JJ, Oriol A, Granada I, Hernandez-Rivas JM, Parody R, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica. 2002;87(2):154-66.
14. Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene. 2006;25 (13):1862-70.
15. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia. 2003;17(12):2474-86.
16. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative realtime RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003; 17(4):789-95.
17. Cobanoglu U, Sonmez M, Ozbas HM, Erkut N, Can G. The expression of LMO2 protein in acute B-cell and myeloid leukemia. Hematology. 2010;15(3):132-4.
18. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64.
19. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCIDX1. J Clin Invest. 2008;118(9):3132-42.
20. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-64.
21. Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood. 2010;116(6):962-70.
22. Honda H, Inaba T, Suzuki T, Oda H, Ebihara Y, Tsuiji K, et al. Expression of E2AHLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. Blood. 1999;93(9):2780-90.
23. Smith KS, Rhee JW, Naumovski L, Cleary ML. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. Mol Cell Biol. 1999;19(6):4443-51.
24. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCRABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536-43.
25. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009;21(1):1-8.